BIM
ATXS

BlackRock Investment Management’s Astria Therapeutics ATXS Stock Holding History

BlackRock Investment Management’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$4K Hold
17
– – ﹤0.01% 3791
2016
Q3 		$6K Buy
17
+4
+31% +$1.05K ﹤0.01% 3734
2016
Q2 		$3K Sell
13
-185
-93% -$55.8K ﹤0.01% 3919
2016
Q1 		$60K Buy
198
+38
+24% +$13.1K ﹤0.01% 3267
2015
Q4 		$76K Buy
160
+4
+3% +$1.92K ﹤0.01% 3294
2015
Q3 		$76K Buy
+156
New +$111K ﹤0.01% 3319

Other funds holding ATXS

SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
CV
Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock Investment Management's ATXS Position: Q4 2016 in Review

BlackRock Investment Management held its Astria Therapeutics (ATXS) position steady in Q4 2016 at 17 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #3791.

BlackRock Investment Management first reported a position in ATXS in Q3 2015 and has held it in 6 quarters since. The position peaked at $76K in Q4 2015. 26 funds tracked by Wall St. Rank hold ATXS as of Q4 2016.

  • BlackRock Investment Management held 17 shares of Astria Therapeutics worth $4K as of Q4 2016.
  • BlackRock Investment Management left its Astria Therapeutics share count unchanged in Q4 2016.
  • Astria Therapeutics made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #3791 holding.
  • BlackRock Investment Management first reported a position in Astria Therapeutics in Q3 2015 and has held it in 6 quarters since.
  • BlackRock Investment Management's Astria Therapeutics position peaked at $76K in Q4 2015.
  • 26 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.